Cite
HARVARD Citation
Singhal, M. et al. (2019). Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. BMJ open diabetes research and care. 7 (1), p. . [Online].